Delving into the Latest Updates on Para-Toluenesulfonamide with Synapse

Pancreatic alpha amylase (P-AMY) is used as a biomarker of acute pancreatitis (AP) in human medicine. To our knowledge, there are no studies evaluating the usefulness of P-AMY in dogs with AP. In this study, we evaluated the diagnostic value of P-AMY, currently not verified in veterinary medicine. The AP group (n = 40) consisted of dogs with AP diagnosed using clinical signs and laboratory examinations, including abnormal canine pancreatic lipase (cPL) concentration, and compatible abdominal ultrasound examination at first presentation. Evaluation of the canine AP severity (CAPS) score was performed. The control group (n = 38) was composed of normal dogs without any abnormalities in clinical findings, blood exams or diagnostic imaging. The correlation of P-AMY with cPL was confirmed by Pearson's correlation analysis (r = 0.564, p < .001). The sensitivity and specificity for the most appropriate cut-off values of P-AMY were recorded similar to the values of DGGR. The dogs with AP and CAPS ≥11 had significantly higher serum P-AMY (p = .016) contrary to DGGR lipase and cPL. Furthermore, there was a significant difference in the median P-AMY dependent on the presence of systemic inflammatory response syndrome (p = .001). P-AMY showed similar level of diagnostic accuracy along with sensitivity and specificity compared to DGGR lipase. In addition, P-AMY showed a significant association with CAPS score, contrary to cPL and DGGR lipase. Along with other biomarkers associated with AP, P-AMY has the potential of usefulness as a supportive diagnostic and prognostic biomarker of AP in dogs.

01 Dec 2024·Talanta

Highly sensitive chemiluminescent sensor for detecting o-toluenesulfonamide and sulfamethoxazole using Cu-doped carbon dots

Article

Author: Yang, Xian ; Han, Hongping ; Zhang, Xue ; Zhao, Yue ; Zheng, Hong ; Xiao, Yujie

01 Dec 2024·International Immunopharmacology

Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway

Article

Author: Li, Shan ; Wang, Baiyan ; Yang, Yi ; Guo, Dandan ; Li, Aifang ; Jin, Guoguo ; Feng, Shuying ; Lu, Baoping ; Shi, Wenjie

Pterostilbene (PTS) is a dietary phytochemical that has shown antitumor activity in many types of cancer, but the molecular mechanism remains unclear. It has also not been adequately studied on PTS against esophageal squamous cell carcinoma (ESCC). Thus, this study investigated the effect of PTS on ESCC in vitro and in vivo and explored the underlying molecular mechanism. We found that PTS can inhibit the proliferation, colony formation, and migration of ESCC cells. According to the bioinformatics analysis of proteomics, PTS had a great influence on the metabolic process of ESCC cells. KEGG analysis showed that PTS down-regulated the pyruvate metabolism pathway. Moreover, PTS can inhibit the PK activity, glucose consumption, and lactate production in ESCC cells. By administration of PTS into xenograft mice, experiment results demonstrated that PTS can suppress tumor progress and the PKM2/STAT3/c-MYC signaling pathway. We found that PTS inhibited the PKM2/STAT3/c-MYC signaling pathway by targeting PKM2 in ESCC cells. Collectively, this study revealed that PTS inhibited ESCC growth by suppressing PKM2 mediated aerobic glycolysis and PKM2/STAT3/c-MYC signaling pathway, which enriching the anti-tumor molecular mechanism of PTS and providing a theoretical basis for its clinical application.

100 Deals associated with Para-Toluenesulfonamide

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 Nov 2022

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenoid Cystic Carcinoma	Phase 1	CN	Tianjin Chase Sun Pharmaceutical Co., Ltd.	15 May 2014
Adenoid Cystic Carcinoma	Phase 1	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 May 2014
Hepatocellular Carcinoma	Phase 1	CN	Tianjin Hongri Jiandakang Medical Technology Co Ltd	15 May 2014
Hepatocellular Carcinoma	Phase 1	CN	Tianjin Chase Sun Pharmaceutical Co., Ltd.	15 May 2014
Airway Obstruction	Phase 1	CN	Beijing Jiandakang New Drug Development Co Ltd	30 Oct 2009
Non-Small Cell Lung Cancer	Phase 1	CN	Pts International Inc	01 Aug 2009
occlusions	Phase 1	CN	Pts International Inc	01 Aug 2009
Advanced Malignant Solid Neoplasm	Phase 1	CN	-	12 Aug 2005
6-Pyruvoyl-Tetrahydropterin Synthase Deficiency	Phase 1	CN	-	22 Apr 2005
Lung Cancer	Phase 1	CN	-	22 Apr 2005